Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

PLX PHARMA INC.

(PLXP)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

PLx Pharma : VAZALORE to Launch in Over 2,400 Rite Aid Stores in August

07/26/2021 | 04:30pm EDT

SPARTA, N.J., July 26, 2021 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuard™ drug delivery platform to provide more effective and safer products, with its lead products VAZALORE™ 325 mg and VAZALORE™ 81 mg (referred to together as “VAZALORE”), today announced that three stock-keeping units (“SKUs”) of VAZALORE, the first and only U.S. Food and Drug Administration (“FDA”) approved liquid-filled aspirin capsules, will be available in over 2,400 Rite Aid stores later in August.

Rite Aid is also reserving shelf space with “Coming Soon” placeholders for all three SKUs -- VAZALORE 81 mg, 12 count; VAZALORE 81 mg, 30 count; and VAZALORE 325 mg, 30 count – to alert consumers about the new aspirin therapy that will soon be available.

“Our commercial launch plans are well under way, and we are delighted that Rite Aid is preparing its stores for VAZALORE later this summer. We look forward to adding Rite Aid to the growing number of retail pharmacy leaders that are providing access to this innovative aspirin therapy,” stated Natasha Giordano, Chief Executive Officer of PLx.

About VAZALORE

VAZALORE is an FDA-approved liquid-filled aspirin capsule that provides patients with vascular disease and diabetic patients who are candidates for aspirin therapy based on physician recommendation, with fast, reliable and predictable platelet inhibition as compared to enteric-coated aspirin. It also reduces the risk of stomach erosions and ulcers, as compared to immediate-release aspirin, common in an acute setting. To learn more about VAZALORE, please visit www.vazalore.com.

About PLx Pharma Inc. 

PLx Pharma Inc. is a specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuard™ drug delivery platform to provide more effective and safer products. The PLxGuard drug delivery platform works by targeting the release of active pharmaceutical ingredients to various portions of the gastrointestinal (GI) tract. PLx believes this platform has the potential to improve the absorption of many drugs currently on the market or in development, and to reduce the risk of stomach erosions and ulcers associated with certain drugs.

To learn more about PLx Pharma Inc. and its pipeline, please visit www.plxpharma.com.

Contact
Investor Relations:
Lisa M. Wilson, In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/63eb4491-f9b7-4c20-9a6b-5cf48bc22c80


Primary Logo

VAZALORE

PLx Pharma Inc.’s VAZALORE to Launch in over 2,400 Rite Aid Stores in August.
Source: PLx Pharma Inc.

2021 GlobeNewswire, Inc., source Press Releases

All news about PLX PHARMA INC.
09/21PLX PHARMA : BWS Financial Initiates Coverage on PLx Pharma With Buy Rating, $29 Price Tar..
MT
09/21PLX PHARMA : Corporate Presentation
PU
09/21PLX PHARMA INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
09/20PLX PHARMA INC.(NASDAQCM : PLXP) added to S&P Global BMI Index
CI
09/09PLX PHARMA : to Present at Upcoming Virtual Healthcare Industry Conferences
AQ
08/26PLX PHARMA : Announces Nationwide Rollout of Aspirin Capsules
MT
08/26PLX PHARMA : VAZALORE™ Now on Shelves; National Media Campaign Launches Today
AQ
08/06PLX PHARMA INC. : Entry into a Material Definitive Agreement, Financial Statements and Exh..
AQ
08/06PLX PHARMA : Q2 Loss Widens
MT
08/06PLX PHARMA : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OP..
AQ
More news
Analyst Recommendations on PLX PHARMA INC.
More recommendations
Financials (USD)
Sales 2021 9,34 M - -
Net income 2021 -48,5 M - -
Net Debt 2021 - - -
P/E ratio 2021 -9,58x
Yield 2021 -
Capitalization 554 M 554 M -
Capi. / Sales 2021 59,3x
Capi. / Sales 2022 16,9x
Nbr of Employees 10
Free-Float 89,5%
Chart PLX PHARMA INC.
Duration : Period :
PLx Pharma Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PLX PHARMA INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Last Close Price 20,59 $
Average target price 24,00 $
Spread / Average Target 16,6%
EPS Revisions
Managers and Directors
Natasha Giordano President, Chief Executive Officer & Director
Rita M. O'Connor CFO, Head-Manufacturing & Supply Chain
Michael J. Valentino Executive Chairman
Gary S. Balkema Independent Director
Kirk K. Calhoun Independent Director
Sector and Competitors
1st jan.Capi. (M$)
PLX PHARMA INC.273.01%554
GILEAD SCIENCES, INC.22.19%89 259
BIONTECH SE309.08%80 542
WUXI APPTEC CO., LTD.34.39%68 685
REGENERON PHARMACEUTICALS32.25%66 425
VERTEX PHARMACEUTICALS-22.31%47 634